Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms

Yoshitaka Inaba; Susumu Hijioka; Isanori Iwama; Tsubasa Asai; Hiroki Miyamura; Shohei Chatani; Takaaki Hasegawa; Shinichi Murata; Mina Kato; Yozo Sato; Hidekazu Yamaura; Hiroaki Onaya; Junichi Shimizu; Kazuo Hara

doi:10.22038/AOJNMB.2021.56254.1390

Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms

Asia Ocean J Nucl Med Biol. 2022 Winter;10(1):1-13. doi: 10.22038/AOJNMB.2021.56254.1390.

Affiliations

¹ Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
² Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
³ Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.

Abstract

Objectives: We investigated the detectability of somatostatin receptor scintigraphy (SRS) for neuroendocrine neoplasms (NEN).

Methods: From January 2016 to October 2020, 125 SRS examinations using indium-111 pentetreotide performed for patients with NEN lesions were retrospectively evaluated. The detection rate of NEN lesions was determined according to histopathological classification by primary site and by organ.

Results: At least one NEN lesion was detected in 73% (91/125) with a positive Krenning score of ≥2 in SRS. The detection of abdominal NENs (gastrointestinal tract, 38; pancreas, 62; and others, 14) was 89% (49/55) for neuroendocrine tumor (NET)-grade (G) 1, 78% (32/41) for NET-G2, 66% (2/3) for NET-G3, 31% (4/13) for neuroendocrine carcinoma (NEC), 100% (1/1) for mixed neuroendocrine-non-neuroendocrine neoplasm, and 0% (0/1) for non-classified NEN. That of thoracic NENs was 33% (2/6) for typical carcinoid tumor and 40% (2/5) for atypical carcinoid tumor. For a total of 226 organ lesions, hepatic lesions were 76% (58/76); pancreatic lesions, 61% (31/51); lymph node lesions, 77% (27/35); bone lesions, 83% (20/24); duodenal lesions, 82% (9/11); and other lesions, 41% (11/27).

Conclusion: The detectability of SRS for NEN in Japan was verified at a center, and its usefulness was confirmed.

Keywords: Indium-111 pentetreotide; Neuroendocrine neoplasms (NEN); Neuroendocrine tumor (NET); Octreo scan; Somatostatin receptor scintigraphy (SRS).